This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Ligand (LGND) Beats on Q3 Earnings & Revenues, Raises View
by Zacks Equity Research
Ligand (LGND) beats earnings and sales estimates in the third quarter of 2018 and raises full-year guidance for the second straight quarter.
Amgen (AMGN) Counts on New Drugs Amid Rising Biosimilar Woes
by Zacks Equity Research
Amgen's newer drugs, Prolia, Xgeva, Kyprolis, are driving sales. Lower sales of mature drugs like Enbrel and biosimilar competition for Neulasta/Epogen are concerns.
The Zacks Analyst Blog Highlights: Amgen, Intercontinental Exchange, TOTAL S.A., Royal Dutch Shell and Williams
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, Intercontinental Exchange, TOTAL S.A., Royal Dutch Shell and Williams
5 Top Stocks to Make the Most of a Divided Congress
by Tirthankar Chakraborty
Gridlock in Washington bodes well for healthcare and defense stocks, which calls for investing in such a space for the time being.
Lilly (LLY) Tops Q3 Earnings, Lifts 2018 Outlook, Stock Up
by Zacks Equity Research
Eli Lilly (LLY) beats estimates for earnings but misses the same for sales. The company raises its previously issued outlook for adjusted earnings. Stock rises in pre-market trading.
Election Day 2018: Here Are the Winners & Losers
by Tirthankar Chakraborty
One of the most awaited midterm elections in American history is upon us. Let's thus look at the sectors most likely to be impacted by the election results.
Top Analyst Reports for Amgen, Intercontinental & TOTAL S.A.
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Amgen (AMGN), Intercontinental Exchange (ICE) and TOTAL S.A. (TOT).
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $189.92, moving +1.53% from the previous trading session.
Radius Health (RDUS) Posts Narrower-Than-Expected Q3 Loss
by Zacks Equity Research
Radius Health (RDUS) posts narrower Q3 loss as Tymlos sales gains traction.
Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO
by Zacks Equity Research
We see how things are shaping up for the four pharma/biotech companies, which are scheduled to release second-quarter earnings on Nov 5.
Teva (TEVA) Q3 Earnings Beat, 2018 EPS View Up, Shares Rise
by Zacks Equity Research
Teva's (TEVA) shares up 15% despite mixed third-quarter results as it increases its earnings and free cash flow guidance for the full year.
Biotech ETFs in Focus on String of Q3 Earnings Beat
by Zacks Equity Research
Biotech ETFs draw attention post impressive Q3 results.
The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals
Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal
by Zacks Equity Research
Impressive third-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.
Amgen (AMGN) Beats on Earnings & Sales in Q3, Raises View
by Zacks Equity Research
Amgen (AMGN) beats estimates for both earnings and sales in Q3 and raises guidance for the full year
The Zacks Analyst Blog Highlights: Facebook, Amgen and MGM Resorts International
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Amgen and MGM Resorts International
Top Ranked Income Stocks to Buy for October 31st
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, October 31st:
Facebook Beats Q3 Estimates, Swings to Positive; Plus AMGN, MGM
by Mark Vickery
Facebook earnings beat by 30 cents from the Zacks consensus to $1.76 per share, and above the $1.59 in the year-ago quarter. However, revenues missed expectations of $13.81 billion, posting $13.73 billion, but are still up roughly 30% year over year.
Amgen (AMGN) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of 7.89% and 1.52%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Community Health's (CYH) Q3 Loss Widens, Admissions Drop
by Zacks Equity Research
Community Health (CYH) suffers from loss from drop in admissions.
Pfizer (PFE) Beats on Q3 Earnings, Meets Sales, Narrows View
by Zacks Equity Research
Pfizer's (PFE) third-quarter earnings beat estimates while sales match the same. The company narrows its full-year sales and profit targets
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
What's in Store for Integer Holdings (ITGR) in Q3 Earnings?
by Zacks Equity Research
The Cardio & Vascular product line to boost Integer Holdings' (ITGR) top line in Q3. The upside will be driven by strong revenues in the peripheral vascular, neurovascular and electrophysiology markets.
Teva (TEVA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.
The Zacks Analyst Blog Highlights: Allergan, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and AMAG Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Allergan, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and AMAG Pharmaceuticals